Kyverna Therapeutics, a late-stage biopharmaceutical company developing cell therapies for autoimmune diseases, announced it will present at the H.C. Wainwright Nasdaq BioConnect Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. These presentations will include investor meetings and corporate updates, highlighting progress on their lead CAR T-cell therapy candidate, miv-cel, which targets B-cell-driven autoimmune diseases. The company is advancing clinical trials in stiff person syndrome and generalized myasthenia gravis, with live webcasts available on their website. This exposure aims to attract investor interest as Kyverna moves toward potential regulatory approvals and expanded clinical development.
Fitness Champs Holdings Limited (FCHL), penyedia pendidikan olahraga air terkemuka di Singapura, akan mengadakan Rapat Umum Pemegang Saham Luar Biasa (RUPSLB) pada 29 Juni 2026, pukul 10 pagi waktu Singapura. Pemegang saham Kelas A dan Kelas B yang t...
Verizon's stock has demonstrated resilience recently compared to other telecom carriers, maintaining its status as a solid defensive investment. Despite poor performance in the last bear market, Verizon offers a strong 6% dividend yield that appears ...
Canary Capital launched the first US spot ETF for Hedera's native token HBAR, trading under ticker HBR on Nasdaq. The ETF holds actual HBAR tokens, not derivatives, with custody by BitGo and Coinbase, and charges a 0.95% fee. This fund provides tradi...
Audiera (BEAT) led crypto gainers with a 53.10% jump to $7.32, driven by increased user adoption and new partnerships in its blockchain-based music streaming platform. Other notable gainers include Provenance Blockchain, Monero, and World Liberty Fin...
AMD posted strong Q1 results with 37.8% revenue growth and a record $2.57 billion in free cash flow, reinforcing positive investor sentiment. Despite high valuation metrics, the company is expected to benefit from new AI infrastructure products shipp...
